In a report released on March 13, Christophe dombu from Kepler Capital maintained a Buy rating on Basilea Pharmaceutica (BSLN – Research ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs ...

Basilea Pharmaceutica has cited its “stringent risk-return criteria” as a reason for not taking up its option to bring a MRSA antibiotic into clinical development. Basilea secured the license ...

Earnings Call Insights: Basilea Pharmaceutica AG (OTC:BPMUF) Q4 2024 Management projects 2025 total revenue at approximately CHF220 million, with a 14% increase in royalty income to CHF110 million.

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced ...

Basilea Pharmaceutica will finally be able to bring its antibiotic ceftobiprole to the US market, around 15 years after the drug was first turned down by the FDA. The US regulator has cleared the ...

The company continues to rely on non-dilutive funding to offset R&D expenses. Basilea reported robust financial results for 2024, driven by Cresemba’s strong performance and significant pipeline ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...